Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 24 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.81 Insider Own35.16% Shs Outstand30.44M Perf Week-0.49%
Market Cap245.65M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float19.74M Perf Month7.74%
Income-24.56M PEG- EPS next Q- Inst Own11.49% Short Float3.06% Perf Quarter78.54%
Sales0.00M P/S- EPS this Y- Inst Trans-5.43% Short Ratio8.36 Perf Half Y103.27%
Book/sh7.19 P/B1.12 EPS next Y- ROA-10.34% Short Interest0.60M Perf Year133.24%
Cash/sh6.57 P/C1.23 EPS next 5Y- ROE-10.69% 52W Range3.05 - 9.96 Perf YTD101.75%
Dividend Est.- P/FCF- EPS past 5Y-6.44% ROI-11.22% 52W High-18.98% Beta1.48
Dividend TTM- Quick Ratio33.07 Sales past 5Y-47.28% Gross Margin-489.67% 52W Low164.59% ATR (14)0.71
Dividend Ex-DateJul 15, 2021 Current Ratio33.07 EPS Y/Y TTM25.52% Oper. Margin0.00% RSI (14)49.50 Volatility9.12% 9.78%
Employees82 Debt/Eq0.00 Sales Y/Y TTM-100.00% Profit Margin- Recom3.00 Target Price10.00
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-44.77% Payout- Rel Volume0.90 Prev Close8.18
Sales Surprise- EPS Surprise- Sales Q/Q-100.00% Earnings- Avg Volume72.33K Price8.07
SMA20-6.49% SMA5010.24% SMA20054.75% Trades Volume64,851 Change-1.34%
Date Action Analyst Rating Change Price Target Change
Jun-14-19Initiated Piper Jaffray Overweight $13
Apr-21-17Downgrade Noble Financial Buy → Hold $13
Jun-28-16Reiterated Noble Financial Buy $24 → $30
Mar-18-24 03:53PM
Jan-04-24 09:00AM
Nov-14-23 09:00AM
Sep-26-23 09:00AM
Aug-30-23 09:00AM
11:47AM Loading…
Aug-08-23 11:47AM
Jul-25-23 11:53AM
Jun-28-23 10:36AM
May-22-23 09:00AM
May-17-23 09:00AM
Apr-17-23 09:00AM
Apr-09-23 10:08AM
Feb-15-23 09:29AM
Jan-19-23 08:02AM
Nov-11-22 05:00AM
09:41AM Loading…
Oct-31-22 09:41AM
Oct-13-22 12:46PM
Sep-08-22 08:59AM
Aug-12-22 08:38AM
Jun-20-22 09:00AM
May-24-22 09:06AM
Apr-28-22 09:00AM
Mar-15-22 11:00AM
Feb-02-22 09:00AM
Jan-26-22 09:50AM
Jan-10-22 10:18AM
Dec-15-21 10:37AM
Dec-13-21 08:00AM
Oct-28-21 11:59AM
11:48AM Loading…
Sep-14-21 11:48AM
Sep-08-21 09:00AM
Aug-30-21 09:00AM
Jul-30-21 11:03AM
Jul-06-21 04:30PM
Jun-30-21 11:46AM
Jun-29-21 08:04AM
Jun-23-21 08:30AM
Jun-16-21 02:52AM
Jun-08-21 03:16PM
May-19-21 09:31AM
May-03-21 08:00AM
Apr-19-21 07:08AM
Mar-18-21 07:51AM
Feb-26-21 03:26PM
Jan-21-21 08:15AM
Jan-19-21 08:15AM
Nov-29-20 08:14PM
Nov-19-20 08:15AM
Sep-22-20 03:25PM
Sep-21-20 08:20AM
Aug-24-20 10:00AM
Aug-17-20 08:20AM
Jul-22-20 09:20AM
Jul-14-20 09:25AM
Jun-22-20 02:17PM
May-01-20 09:25AM
Apr-17-20 08:45PM
Apr-14-20 09:15AM
Apr-03-20 04:53PM
Feb-19-20 08:15AM
Feb-13-20 01:24PM
Feb-10-20 03:59PM
Jan-15-20 08:22AM
Jan-14-20 08:30AM
Dec-30-19 04:05PM
Dec-20-19 02:53PM
Dec-17-19 08:15AM
Dec-10-19 07:14AM
Dec-07-19 03:05AM
Nov-19-19 08:55AM
Nov-12-19 08:45AM
Oct-23-19 08:15AM
Oct-10-19 02:57PM
Oct-02-19 08:59AM
Sep-27-19 08:15AM
Sep-20-19 08:15AM
Jul-16-19 01:15PM
Jul-11-19 08:30AM
Jul-10-19 08:00AM
Jul-09-19 08:00AM
Jun-26-19 08:30AM
Jun-25-19 08:45AM
Jun-11-19 08:00AM
Jun-04-19 04:01PM
May-31-19 08:47AM
May-30-19 04:32PM
May-23-19 08:20AM
May-13-19 09:27AM
May-02-19 08:15AM
Apr-29-19 07:54AM
Mar-04-19 01:44PM
Mar-01-19 12:54PM
Feb-07-19 11:19AM
Feb-06-19 02:20PM
Jan-29-19 08:15AM
XBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. Its product pipeline includes oncology, infectious diseases, dermatology and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.